Autopsy report · NCT04113187

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

“target number of subject not reached”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 15 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University Hospital, Bordeaux

Sponsor type

University, hospital or other

Conditions

Hereditary Hemorrhagic Telangiectasia; Osler Weber Rendu Disease

Interventions

Propranolol treatment; Placebo

Participants

15

Sites

1

Countries

France

Trials that died the same way

• Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults
  “Target number of subject not reached, termination due to recruitement contraints” (74% match in meaning)
• Pathophysiology Analysis of "Costello Syndrome" on Cellular Models
  “Target number of inclusion not reached” (68% match in meaning)
• Assessment of Inspiratory Muscles Strength and Endurance Evolution on Difficult to Wean Patients in Intensive Care Unit
  “target number of inclusion no reached” (65% match in meaning)
• Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
  “Target recruitment not reached” (60% match in meaning)
• Lovaza Therapy of Peripheral Arterial Disease
  “No subject meeting criteria” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.